Cargando…

Prediction using T2‐weighted magnetic resonance imaging‐based radiomics of residual uterine myoma regrowth after high‐intensity focused ultrasound ablation

OBJECTIVES: To develop and evaluate magnetic resonance imaging (MRI)‐based radiomics models for predicting residual myoma regrowth within 1 year after high‐intensity focused ultrasound (HIFU) ablation of uterine myomas. METHODS: A retrospective analysis of residual myoma regrowth within 1 year was p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Y., Zhang, J., Chen, J., Yang, C., Gong, C., Li, C., Li, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828488/
https://www.ncbi.nlm.nih.gov/pubmed/36054291
http://dx.doi.org/10.1002/uog.26053
_version_ 1784867285224128512
author Zhou, Y.
Zhang, J.
Chen, J.
Yang, C.
Gong, C.
Li, C.
Li, F.
author_facet Zhou, Y.
Zhang, J.
Chen, J.
Yang, C.
Gong, C.
Li, C.
Li, F.
author_sort Zhou, Y.
collection PubMed
description OBJECTIVES: To develop and evaluate magnetic resonance imaging (MRI)‐based radiomics models for predicting residual myoma regrowth within 1 year after high‐intensity focused ultrasound (HIFU) ablation of uterine myomas. METHODS: A retrospective analysis of residual myoma regrowth within 1 year was performed on 428 myomas in 339 patients who were diagnosed with uterine myoma and treated with HIFU ablation in two hospital centers. In total, 851 radiomics features were extracted from T2‐weighted images (T2WI) obtained 1 day after HIFU ablation, and the least absolute shrinkage and selection operator in the training cohort (n = 243) was employed to select radiomics features. Support vector machines were adopted to develop radiomics, clinicoradiological and combined radiomics–clinical models to predict residual myoma regrowth, defined as an increase in residual myoma volume of > 10% between that at day 1 post HIFU and that at follow‐up MRI within 1 year. These models were validated in both internal (n = 81) and external (n = 104) test cohorts. The predictive performance and clinical application of these models were assessed using receiver‐operating‐characteristics‐curve analysis, the area under the curve (AUC) and decision‐curve analysis. RESULTS: The AUCs of the T2WI‐based radiomics prediction model in the internal and external test cohorts were 0.834 (95% CI, 0.747–0.920) and 0.801 (95% CI, 0.712–0.889), respectively, and those of the clinicoradiological model were 0.888 (95% CI, 0.816–0.960) and 0.912 (95% CI, 0.851–0.973), respectively. The combined model had better predictive performance than either the radiomics or the clinicoradiological model, with AUC values of 0.922 (95% CI, 0.857–0.987) and 0.930 (95% CI, 0.880–0.980) in the internal and external test cohorts, respectively. Decision‐curve analysis also indicated that application of the combined model has clinical value, this model achieving more net benefits than the other two models. CONCLUSION: T2WI‐based radiomics features can predict effectively the occurrence of residual myoma regrowth within 1 year after HIFU ablation of uterine myomas, which serves as an accurate and convenient reference for clinical decision‐making. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
format Online
Article
Text
id pubmed-9828488
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Ltd.
record_format MEDLINE/PubMed
spelling pubmed-98284882023-01-10 Prediction using T2‐weighted magnetic resonance imaging‐based radiomics of residual uterine myoma regrowth after high‐intensity focused ultrasound ablation Zhou, Y. Zhang, J. Chen, J. Yang, C. Gong, C. Li, C. Li, F. Ultrasound Obstet Gynecol Original Papers OBJECTIVES: To develop and evaluate magnetic resonance imaging (MRI)‐based radiomics models for predicting residual myoma regrowth within 1 year after high‐intensity focused ultrasound (HIFU) ablation of uterine myomas. METHODS: A retrospective analysis of residual myoma regrowth within 1 year was performed on 428 myomas in 339 patients who were diagnosed with uterine myoma and treated with HIFU ablation in two hospital centers. In total, 851 radiomics features were extracted from T2‐weighted images (T2WI) obtained 1 day after HIFU ablation, and the least absolute shrinkage and selection operator in the training cohort (n = 243) was employed to select radiomics features. Support vector machines were adopted to develop radiomics, clinicoradiological and combined radiomics–clinical models to predict residual myoma regrowth, defined as an increase in residual myoma volume of > 10% between that at day 1 post HIFU and that at follow‐up MRI within 1 year. These models were validated in both internal (n = 81) and external (n = 104) test cohorts. The predictive performance and clinical application of these models were assessed using receiver‐operating‐characteristics‐curve analysis, the area under the curve (AUC) and decision‐curve analysis. RESULTS: The AUCs of the T2WI‐based radiomics prediction model in the internal and external test cohorts were 0.834 (95% CI, 0.747–0.920) and 0.801 (95% CI, 0.712–0.889), respectively, and those of the clinicoradiological model were 0.888 (95% CI, 0.816–0.960) and 0.912 (95% CI, 0.851–0.973), respectively. The combined model had better predictive performance than either the radiomics or the clinicoradiological model, with AUC values of 0.922 (95% CI, 0.857–0.987) and 0.930 (95% CI, 0.880–0.980) in the internal and external test cohorts, respectively. Decision‐curve analysis also indicated that application of the combined model has clinical value, this model achieving more net benefits than the other two models. CONCLUSION: T2WI‐based radiomics features can predict effectively the occurrence of residual myoma regrowth within 1 year after HIFU ablation of uterine myomas, which serves as an accurate and convenient reference for clinical decision‐making. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology. John Wiley & Sons, Ltd. 2022-11-01 2022-11 /pmc/articles/PMC9828488/ /pubmed/36054291 http://dx.doi.org/10.1002/uog.26053 Text en © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Zhou, Y.
Zhang, J.
Chen, J.
Yang, C.
Gong, C.
Li, C.
Li, F.
Prediction using T2‐weighted magnetic resonance imaging‐based radiomics of residual uterine myoma regrowth after high‐intensity focused ultrasound ablation
title Prediction using T2‐weighted magnetic resonance imaging‐based radiomics of residual uterine myoma regrowth after high‐intensity focused ultrasound ablation
title_full Prediction using T2‐weighted magnetic resonance imaging‐based radiomics of residual uterine myoma regrowth after high‐intensity focused ultrasound ablation
title_fullStr Prediction using T2‐weighted magnetic resonance imaging‐based radiomics of residual uterine myoma regrowth after high‐intensity focused ultrasound ablation
title_full_unstemmed Prediction using T2‐weighted magnetic resonance imaging‐based radiomics of residual uterine myoma regrowth after high‐intensity focused ultrasound ablation
title_short Prediction using T2‐weighted magnetic resonance imaging‐based radiomics of residual uterine myoma regrowth after high‐intensity focused ultrasound ablation
title_sort prediction using t2‐weighted magnetic resonance imaging‐based radiomics of residual uterine myoma regrowth after high‐intensity focused ultrasound ablation
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828488/
https://www.ncbi.nlm.nih.gov/pubmed/36054291
http://dx.doi.org/10.1002/uog.26053
work_keys_str_mv AT zhouy predictionusingt2weightedmagneticresonanceimagingbasedradiomicsofresidualuterinemyomaregrowthafterhighintensityfocusedultrasoundablation
AT zhangj predictionusingt2weightedmagneticresonanceimagingbasedradiomicsofresidualuterinemyomaregrowthafterhighintensityfocusedultrasoundablation
AT chenj predictionusingt2weightedmagneticresonanceimagingbasedradiomicsofresidualuterinemyomaregrowthafterhighintensityfocusedultrasoundablation
AT yangc predictionusingt2weightedmagneticresonanceimagingbasedradiomicsofresidualuterinemyomaregrowthafterhighintensityfocusedultrasoundablation
AT gongc predictionusingt2weightedmagneticresonanceimagingbasedradiomicsofresidualuterinemyomaregrowthafterhighintensityfocusedultrasoundablation
AT lic predictionusingt2weightedmagneticresonanceimagingbasedradiomicsofresidualuterinemyomaregrowthafterhighintensityfocusedultrasoundablation
AT lif predictionusingt2weightedmagneticresonanceimagingbasedradiomicsofresidualuterinemyomaregrowthafterhighintensityfocusedultrasoundablation